RedHill Biopharma (RDHL) Tops Q4 EPS Views

RedHill Biopharma (NASDAQ: RDHL) reported Q4 EPS of $0.06, $0.66 better than the analyst estimate of ($0.60).

EPS in Q413 was 0.05.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Carnival Corp. (CCL) Tops Q2 EPS by 8c, Beats on Revenue; Offers Guidance